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It has been said that “America is a society drunk not on alcohol
but on random factlets wrestled from scientific journals before
the ink has dried.” Stephen Paget said that medical “practice is
science touched with emotion”; conversely, it may also be true
that medical practice is emotion touched with science. Dr.
William Parmley, Editor-in-Chief of the Journal, has reiterated
the importance of these issues in his rule No. 7 from “Guide-
lines for the Interposed Editorial,” which states “Be cautious in
accepting new ideas and techniques. Experience has shown
that the first report may be more enthusiastic than subsequent
reports” (1).
These sentiments and guidelines were applied stringently to
the field of primary coronary angioplasty for acute myocardial
infarction. Although single- and multicenter reports from early
studies documented improved outcome in these series (2–5),
and although a meta-analysis (6) (for all the potential meth-
odologic problems with meta-analyses) also suggested benefit,
controversy existed and persists today as to which is better—
primary angioplasty or thrombolysis for acute myocardial
infarction.
Depending on the end point used for comparison, random-
ized trial results and conclusions may differ. The importance of
the end point used on the conclusion is illustrated by an
analysis of several potential comparison end points of PTCA
versus thrombolysis for acute infarction.
1. For example, for an end point of infarct-related artery
patency and Thrombolysis in Myocardial Infarction (TIMI)
grade 3 flow, after treatment, primary angioplasty clearly
provides an improved outcome compared with that after
thrombolytic therapy. This difference may even widen because
the use of glycoprotein IIb/IIIa inhibitors and stents may even
further optimize TIMI flow after PTCA. In contrast, attempts
to increase the potency of thrombolytic therapy have been
limited by the increased potential for cerebral hemorrhage.
Accordingly, PTCA would be considered superior if this was
the end point assessed.
2. For an end point of recurrent ischemia, primary angio-
plasty decreases this event and the need for subsequent
revascularization. Again, with recurrent ischemia as an end
point, PTCA would be found to be superior to thrombolysis.
3. For an end point of a decrease in mortality in very high
risk patients, the preponderance of the data suggests that
primary angioplasty provides substantial incremental benefit
compared with lytic therapy in this patient group. This benefit
is clearly important for the higher risk patient (e.g., patients
with cardiogenic shock (7).
4. For an end point of whether the therapy can be used even
if there is no cardiac laboratory or cardiologist available, there
is a clear winner. If this is the end point to be tested for
comparing PTCA with lytic therapy, the answer is obvious; this
is a major strength of thrombolytic therapy. In areas without
access to catheterization laboratories, reperfusion begins and
ends with thrombolysis.
5. Finally, for an end point of mortality alone (i.e., no
combined end point), there may be variable results, depending
on the specific subset of patients studied. If a study enrolled a
preponderance of low risk patients, differences between
thrombolysis and PTCA would most likely be very small,
possibly even nonexistent, in contrast to studies involving a
larger number of high risk patients; when high risk patients are
included, PTCA appears to be substantially better.
Zijlstra et al. (8), in the current issue of the Journal, have
evaluated the strategy of patient care. The authors have an
expert background in myocardial infarction trials, having con-
ducted one of the three pivotal early randomized trials of
PTCA versus thrombolytic therapy. In the current study, they
have gone further to evaluate the crucial questions of patient
care by designing a strategy study of primary angioplasty for
high risk patients and thrombolysis for low risk patients. Many
clinical practices are based on this exact concept of patient
triage. The primary end point was a combined one—death and
nonfatal stroke or reinfarction during a 6-month follow-up
period, with left ventricular ejection fraction and cost as
secondary end points.
In their study, Zijlstra et al. used the readily available
clinical criteria for risk stratification: 1) contraindications for
thrombolytic therapy; 2) Killip class .II or III; 3) anterior
myocardial infarction; and 4) an extensive nonanterior myo-
cardial infarction with eight or more leads with ST segment
elevation or depression to identify high risk patients. Dilation
was performed in these patients; the other patients were
considered, and were defined as, low risk. These low risk
patients were randomized to undergo PTCA or to receive 1.5
mU of intravenous streptokinase. The sample size was based
on an incidence of death and nonfatal stroke of 3% and
nonfatal reinfarction of 12% after 6 months for low risk
patients and was calculated to be 296. The total number of
patients expected for full trial enrollment was at least 500 (both
low and high risk). The trial was stopped prematurely at the
time of a planned interim analysis of 150 patients.
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Of the total of 240 patients entered, 39% were low risk; 50
of them were treated with thrombolytic therapy. The primary
combined end point of death and nonfatal stroke or reinfarc-
tion was markedly different in the low risk patients; it was
reached in only 4% of low risk patients randomized to undergo
PTCA compared with 20% of those receiving thrombolysis
(p , 0.02). In the low risk group, the overall mortality rate was
only 1%. Strikingly, in the 145 high risk patients treated with
PTCA, the primary clinical end point was lower at 14% than in
the low risk patients treated with thrombolysis, of whom 20%
had an adverse primary combined end point, particularly as a
result of decreasing reinfarction. PTCA was carried out expe-
ditiously, with a mean (6SD) time from hospital admission to
first balloon inflation of 68 6 21 min. PTCA was also carried
out expertly, with a procedural success rate of 93%.
Zijlstra et al. point out that in their study, they attempted to
tailor the reperfusion strategy to the specific patient, clearly an
important goal for all physicians and an even more important
goal for all patients. To achieve this goal, they used simple,
inexpensive clinical data that could be applied rapidly. These
data formed the basis for the therapeutic strategy to be tested.
The striking finding was that even in low risk patients, primary
coronary angioplasty resulted in a better outcome when the
combined end point of death and nonfatal stroke or reinfarc-
tion was used. In the high risk patients, the combined end point
was lower than in the low risk patients treated with thrombol-
ysis. Secondary end points were also an important consider-
ation. As might be expected, total medical costs were higher in
the high risk patients. In low risk patients, the cost of an
invasive PTCA approach was not different from that for
thrombolysis, and indeed, the costs per event-free survivor
were lower in the former. Finally, stroke rates were not
different between the low risk patients treated with thrombol-
ysis and those undergoing PTCA, although other studies have
documented an increase in stroke rate with lytic therapy.
Fortunately, the number of these events in the current study
was low.
How does this study relate to rule No. 7? Early on, there
was justified caution in interpreting the results of primary
angioplasty for acute myocardial infarction; specifically, there
was concern that the procedure was being carried out by
zealots with good hands. However, with accumulating data,
such as those presented by Zijlstra et al., there is less emotion
and more science. It becomes increasingly clear that the
interventional cardiologist will have to continue to get up at
night and on weekends because with an existing expert infra-
structure for interventional cardiology and rapid access to it,
all patients with an acute myocardial infarction and ST seg-
ment elevation can benefit from immediate coronary angiog-
raphy and coronary angioplasty.
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Abbreviations and Acronyms
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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